Advaxis Secures $23 Million Financing

Last week, Advaxis, Inc. (a clinical-stage biotechnology company developing cancer immunotherapies on its proprietary Lm-LLO platform technology), announced that a combined $23 million of purchase agreements was raised, worth approximately 3.1 million shares, at a price of $7.50 per share from several institutional investors. The investors include Adage Capital Management, L.P. Broadfin Capital LLC, Sectoral Asset Management, Cormorant Asset Management and …

Brochure Available for the World Vaccine Congress

1 Event, 7 Conferences at the World Vaccine Congress 2015 The World Vaccine Congress is back for it’s 15th year on April 7-9 in Washington. With over 250 people already signed up to attend, ranging from pharma and biotech, to non-profits and governmental departments, it is set to be another great year. The event has grown for 2015. Not only …

Michael Hanna Vaccinogen cancer vaccine prostate cancer

The Problem with Cancer Vaccines

  You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeaway message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tumour cell vaccine OncoVAX, to discuss why there have been so many high-profile cancer vaccine failures and how this has affected …

How do you bridge the gap between prophylactic and therapeutic vaccines?

How do you bridge the gap between prophylactic and therapeutic vaccines? "A vaccine that ‘treats' a disease before it causes morbidity would bridge the gap between prophylactics and therapeutics."But how? Download this presentation to discover more about bridging the gap between prophylactic and therapeutic vaccines including: · The next-best thing to prophylaxis · Therapy of still-healthy patients requires validated biomarkers …

Novel vaccine adjuvant for induction of cellular and humoral immunity

Dr Vincent Serra, Chief Executive Officer and Chief Scientific Officer, Wittycell  joined us at the World Vaccine Congress Lyon 2012 to discuss how Wittycell is developing novel vaccines and adjuvant products for both the therapeutic and prophylactic markets, with a focus on T cell response. Their Goal :OVA transfected cell line with OVA as antigen is a really good model …

Sipuleucel-T: An Autologous Cellular Immunotherapy for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Dr Andy Stubbs the Senior Medical Director at Dendreon joined us at the World Vaccine Congress Washington to talk to us about Sipuleucel-T, an autologous Cellular Immunotherapy for patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. Dr Stubbs guided us through the following: Introduction to prostate cancer Natural History of Prostate Cancer Overview of sipuleucel-T & Pre-clinical …

Looking to the Future: Innovative Approaches to #HIV #Vaccine Development and Immunotherapies

We had the pleasure of welcoming Dr Charles Nicolette, the Chief Scientific Officer and R&D Vice President at Argos Therapeutics at the most recent World Vaccine Congress Washington in April to hear about his work on personalised HIV treatment to patient's own virus strain. Dr Nicolette shared his findings on personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other …

Download: Discover the 6 key growth areas in the #vaccine industry

As the vaccine industry grows year on year, isn’t it essential you benchmark your strategies against the competition? With this in mind we organized this year’s World Vaccine Congress Lyon, focusing on precisely those top 6 key growth areas that will help you stay at the forefront of the industry. Expert speakers and industry strategists will come together in Lyon …

How can breakthrough technology serve the emerging markets?

In January 2010 Johan Van Hoof was appointed Global Therapeutic Area Head for Infectious Diseases & Vaccines, Pharmaceuticals Group, JnJ. As of June 2011, Johan took additional responsibilities, as COO Crucell, the Vaccine Company acquired by JnJ in February 2011. In this role he oversees Development and Manufacturing as Crucell. Entering the field of vaccines, J&J aims to broaden its …